0001209191-22-040356.txt : 20220701 0001209191-22-040356.hdr.sgml : 20220701 20220701185505 ACCESSION NUMBER: 0001209191-22-040356 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220629 FILED AS OF DATE: 20220701 DATE AS OF CHANGE: 20220701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRASAD SUYASH CENTRAL INDEX KEY: 0001679129 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 221062744 MAIL ADDRESS: STREET 1: C/O AUDENTES THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY ST., SUITE 2650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-29 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001679129 PRASAD SUYASH C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, STE 1430 DALLAS TX 75247 0 1 0 0 CMO and Head of R&D Common Stock 2022-06-29 4 S 0 12324 3.81 D 581265 D Common Stock 2022-06-30 4 S 0 13892 3.72 D 567373 D Common Stock 2022-07-01 4 S 0 23923 3.53 D 543450 D The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.64 to $3.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.81, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.82, inclusive. /s/ Kamran Alam, Attorney-in-Fact 2022-07-01